department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

835 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT797 Endpoints601 BioPharma Dive231 onclive165 Fierce Biotech72 BioSpace69 raps29

therapy area

all Oncology81 Cardiology27 Psychiatry & CNS21 Vaccines17 Immunology17 Rare Disease12 Hepatology6

<![CDATA[Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL]]>
<![CDATA[Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.]]>
onclive · 2mo ago↗ source
<![CDATA[The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer]]>
<![CDATA[Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreat…
onclive · 2mo ago↗ source
<![CDATA[Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study ]]>

page 27 of 34

Infectious Disease4

<![CDATA[This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea…

onclive · 2mo ago↗ source

<![CDATA[First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC]]>

<![CDATA[Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.]]>

onclive · 2mo ago↗ source

<![CDATA[Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability]]>

<![CDATA[This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and st…

onclive · 2mo ago↗ source

Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech

→ It didn’t take long for Natalie Holles to rebound after the decision to wind down operations at her previous company. She has replaced Elisabet de los Pinos as CEO of ...

Endpoints · 2mo ago↗ source

Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prep

Capricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…

Endpoints · 2mo ago↗ source

Odyssey raises more than $300M as biotech goes public

Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The b…

Endpoints · 2mo ago↗ source

<![CDATA[Dr Sznol on Optimal Treatment Sequencing in Melanoma]]>

<![CDATA[Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data. ]]>

onclive · 2mo ago↗ source

Astellas touts data from early test of stem cell-derived eye therapy

Astellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The…

Endpoints · 2mo ago↗ source

<![CDATA[Mentorship Is Key to Advance the Next Generation of Oncology Researchers]]>

<![CDATA[Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators. ]]>

onclive · 2mo ago↗ source

<![CDATA[Dr Mauro on the Significance of Alternative TKI Formulations in CML]]>

<![CDATA[Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.]]>

onclive · 2mo ago↗ source

<![CDATA[Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn]]>

<![CDATA[Timothy N. Clinton, MD, and Stephanie A. Berg, DO, discuss gender differences in bladder cancer during Bladder Cancer Awareness Month.]]>

onclive · 2mo ago↗ source

Amazon adds Ozempic pill to same-day prescription drug kiosks

The Ozempic pill is coming to Amazon Pharmacy’s prescription drug kiosks. It’s an expansion for the kiosks, which operate like vending machines and have been stocking oral Wegovy since February.…

Endpoints · 2mo ago↗ source

<![CDATA[Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC]]>

<![CDATA[Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.]]>

onclive · 2mo ago↗ source

<![CDATA[Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer]]>

<![CDATA[Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.]]>

onclive · 2mo ago↗ source

<![CDATA[Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.]]>

<![CDATA[Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.]]>

onclive · 2mo ago↗ source

EnGene's shares crash on updated pivotal bladder cancer data

EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech'…

Endpoints · 2mo ago↗ source

Are health insurers out of the woods after a tough 2025?

Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...

Endpoints · 2mo ago↗ source

Blackstone puts $250M into Anagram to tackle cystic fibrosis complication

Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…

Endpoints · 2mo ago↗ source

<![CDATA[FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease]]>

<![CDATA[The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.]]>

onclive · 2mo ago↗ source

<![CDATA[ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies]]>

<![CDATA[Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>

onclive · 2mo ago↗ source

Entrada stock falls on Duchenne data; Wegovy expands access

Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...

Endpoints · 2mo ago↗ source

Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany

Plus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was establishe…

Endpoints · 2mo ago↗ source

Atara, Pierre Fabre's cell therapy to get another shot at FDA approval

There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an…

Endpoints · 2mo ago↗ source